Review

Aspirin in Primary and Secondary Prevention in Elderly Adults Revisited

Authors: Ryan Wilson, MD, Jawahar Gazzala, MD, Jeff House, DO

Abstract

Despite the frequency and long duration of aspirin use, its role in primary and secondary prevention in older adults is not well studied. This review takes a critical look at the available literature on aspirin efficacy in elderly adults, and some relevant guidelines for practicing physicians are suggested.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (suppl 1): 258–261.
 
2. Peto R, Gray R, Collins R, et al.. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–316.
 
3. Steering Committee of the Physicians’ Health Study (PHS) Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129–135.
 
4. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233–241.
 
5. Hansson L, Zanchetti A, Carruthers SG, et al.. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.
 
6. Sacco M, Pellegrini F, Roncaglioni MC, et al.. Collaborative Group. Primary prevention (PPP) of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264–3272.
 
7. Murphy SA. Women’s Health Study (WHS): low dose aspirin in primary prevention. J Am Coll Cardiol 2005; 46: CS7–CS8.
 
8. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295–1302.
 
9. Antiplatelets Trialists’ Collaboration, Baigent C, Blackwell L, Collins R, et al.. Collaborative overview of randomized trials of antiplatelets therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81–106.
 
10. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006; 98: 746–750.
 
11. Berger JS, Roncaglioni MC, Avanzini F, et al.. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306–313.
 
12. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405–410.
 
13. Nelson MR, Reid CM, Ames DA, et al.. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the Aspirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105–109.
 
14. 14. Smith D. Personal stroke risk (over the next 10 years). Available at: www.westernstroke.org/PersonalstrokeRisk1.xls. Accessed November 16, 2011.
 
15. Ogawa H, Nakayama M, et al.. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial (JPAD). JAMA 2008; 300: 2134–2141.
 
16. Belch J, MacCuish A, Campbell I, et al.. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
 
17. Pignone M, Alberts MJ, et al.. Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes. A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33: 1395–1402.
 
18. De Berardis G, Sacco M, Strippoli GF, et al.. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomized controlled trials. BMJ 2009; 339.
 
19. Zhang C, Sun A, Zhang P, et al.. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 87: 211–218.
 
20. Bulpitt CJ. Secondary prevention of coronary heart disease in the elderly. Heart 2005; 91: 396–400.
 
21. Antiplatelets Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelets therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
 
22. Mahé I, Leizorovicz A, Caulin C, et al.. Aspirin for the prevention of cardiovascular events in the elderly. Drugs Aging 2003; 20: 999–1010.
 
23. Caplan LR, Kasner SE, Dashe JF. Clinical diagnosis of stroke subtypes. Up To Date. Last literature review version 18.2: May 2010. Topic Updated: June 2010. http://www.uptodate.com/contents/clinical-diagnosis-of-stroke-subtypes?source=search_result&search=clinical+diagnosis+of+stroke+subtypes&selectedTitle=1%7E150. Accessed December 23, 2011.
 
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–360.
 
25. Krumholz HM, Radford MJ, Ellerbeck EF, et al.. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124: 292–298.
 
26. Maggioni AP, Maseri A, Fresco C, et al.. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell’lnfarto Miocardio (GISSI-2). N Engl J Med 1993; 329: 1442–1448.
 
27. Silagy CA, McNeill JJ, Donnan GA, et al.. The PACE pilot study: 12 month results and implications for future primary prevention trials in the elderly (prevention with low-dose aspirin of cardiovascular disease in the elderly). J Am Geriatr Soc 1994; 42: 643–647.
 
28. Nakashima S, Ota S, Arai S, et al.. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol 2009; 15: 727–731.
 
29. Sung JJ. Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users? Aliment Pharmacol Ther 2009; 20 (suppl 2): 65–70.
 
30. Chan FK, Ching JY, Suen BY, et al.. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001; 344: 967–973.
 
31. Lai KC, Lam SK, Chu KM, et al.. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–2038.